AstraZeneca Pharma India Limited has informed the Exchange regarding 'Launch of Eculizumab (Soliris)'.
ASTRAZEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
AstraZeneca Pharma India has announced the launch of Eculizumab, branded as Soliris, in India starting August 2025. This follows the receipt of Import and Market Permission (Form CT-20) from the Drug Controller General of India (DCGI) in January 2025 for the 300 mg concentrate for solution for infusion (10 mg/ml). Soliris is indicated for treating rare blood disorders, specifically Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (aHUS), by inhibiting complement-mediated thrombotic microangiopathy. The launch expands the company's portfolio into specialty and rare disease therapies in the Indian market.
This product launch strengthens AstraZeneca Pharma India's specialty therapy portfolio and adds a high-value rare disease drug to its offerings. While the patient pool for PNH and aHUS is small, the drug typically commands premium pricing, potentially contributing positively to incremental revenue and margins.